ストックスクリーナーアプリを入手
12.85
1.69%
0.1216
前日終値:
$12.73
開ける：
$12.81
24時間の取引高:
475.11K
Relative Volume:
1.22
時価総額：
$766.15M
収益：
$5.03M
当期純損益:
$-185.41M
株価収益率:
-4.6904
EPS:
-2.74
ネットキャッシュフロー:
$-139.79M
1週間 パフォーマンス:
+0.74%
1か月 パフォーマンス:
-11.70%
6か月 パフォーマンス:
-11.27%
1年 パフォーマンス:
-8.45%
1日の値動き範囲:
$12.52
$13.12
1週間の範囲:
$11.76
$13.12
52週間の値動き範囲:
$10.22
$19.62
Pliant Therapeutics Inc Stock (PLRX) Company Profile
名前
Pliant Therapeutics Inc
セクター
電話
650-481-6770
住所
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
PLRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| PLRX | 12.87 | 766.15M | 5.03M | -185.41M | -139.79M | -2.74 |
| VRTX | 448.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.76 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.05 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.12 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 104.07 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-18 | 開始されました | Canaccord Genuity | Buy |
| 2023-04-13 | 開始されました | Robert W. Baird | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-07 | 開始されました | JP Morgan | Overweight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Outperform |
| 2022-05-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-03 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-20 | 開始されました | BTIG Research | Buy |
| 2021-04-05 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Citigroup | Buy |
| 2020-06-29 | 開始されました | Cowen | Outperform |
| 2020-06-29 | 開始されました | Needham | Buy |
| 2020-06-29 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Pliant Therapeutics Inc (PLRX) 最新ニュース
Pliant Therapeutics to Participate in Upcoming Investor Events - The Manila Times
Pliant Therapeutics to Present at 4 Major Healthcare Conferences in December | PLRX Stock News - StockTitan
Pliant Therapeutics Reports Increased Losses and Strategic Focus - TipRanks
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire
Pliant's Bexotegrast Shows Strong Phase 2 Results in Liver Disease Treatment Trial | PLRX Stock News - StockTitan
Redmile Group, LLC Adjusts Stake in Pliant Therapeutics Inc - GuruFocus.com
First Light Asset Management's Strategic Reduction in Pliant The - GuruFocus.com
Objective long/short (PLRX) Report - Stock Traders Daily
Pliant Therapeutics maintains stock target with Buy rating on clinical trial - Investing.com UK
Stifel maintains Buy on Pliant Therapeutics, target at $32 By Investing.com - Investing.com UK
HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Possible Bearish Signals With Pliant Therapeutics Insiders Disposing Stock - Simply Wall St
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat
Pliant Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times
Pliant Therapeutics to Present at Stifel 2024 Healthcare Conference | Key Leadership Insights | PLRX Stock News - StockTitan
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat
SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance
Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - US Post News
Pliant Therapeutics Inc’s Mixed Bag: Down -3.53% in 6 Months, Down 15.29% in 30 Days - The InvestChronicle
An Analysis of Pliant Therapeutics Inc (PLRX)’s Potential Price Growth - Knox Daily
The Manufacturers Life Insurance Company Purchases 1,191 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
How To Trade (PLRX) - Stock Traders Daily
Pliant Therapeutics (NASDAQ:PLRX) Trading 4.5% HigherStill a Buy? - MarketBeat
Pliant Therapeutics Inc [PLRX] Stock sold by Insider Lefebvre Eric for $0.14 million - Knox Daily
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Squarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Algert Global LLC Increases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance
Pliant Therapeutics stock hits 52-week low at $10.24 - Investing.com
Pliant Therapeutics appoints new SVP of Medical Affairs - Investing.com India
Pliant Therapeutics stock hits 52-week low at $10.24 By Investing.com - Investing.com Australia
Pliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $10.24 - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $10.24 - Defense World
Investor’s Toolkit: Key Ratios for Assessing Pliant Therapeutics Inc (PLRX)’s Performance - The Dwinnex
American Century Companies Inc. Has $797,000 Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs - GlobeNewswire
Lululemon Athletica (LULU-Q) QuotePress Release - The Globe and Mail
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Renaissance Technologies LLC - Defense World
Ensign Peak Advisors Inc Grows Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian
11,678 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by Deerfield Management Company L.P. Series C - Defense World
Pliant Therapeutics updates bylaws, aligns with Delaware law By Investing.com - Investing.com South Africa
Pliant Therapeutics Inc (PLRX) 財務データ
収益
当期純利益
現金流量
EPS
Pliant Therapeutics Inc (PLRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hull Hans | Chief Business Officer |
Jul 10 '24 |
Sale |
11.56 |
9,900 |
114,444 |
227,494 |
| Cummings Keith Lamont | Chief Financial Officer |
Jul 10 '24 |
Sale |
11.56 |
10,911 |
126,131 |
282,115 |
| Coulie Bernard | President and CEO |
Jul 10 '24 |
Sale |
11.56 |
38,710 |
447,488 |
482,936 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jul 10 '24 |
Sale |
11.56 |
7,656 |
88,503 |
94,044 |
| Cummings Keith Lamont | Chief Financial Officer |
May 02 '24 |
Option Exercise |
2.08 |
21,000 |
43,680 |
271,713 |
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '24 |
Sale |
17.23 |
9,781 |
168,527 |
194,605 |
| Hull Hans | Chief Business Officer |
Jan 17 '24 |
Sale |
17.23 |
9,786 |
168,613 |
185,069 |
| Coulie Bernard | President and CEO |
Jan 17 '24 |
Sale |
17.23 |
25,721 |
443,173 |
316,382 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '24 |
Sale |
17.23 |
10,295 |
177,383 |
156,920 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '24 |
Sale |
17.23 |
5,197 |
89,544 |
55,246 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):